{"protocolSection": {"identificationModule": {"nctId": "NCT00941798", "orgStudyIdInfo": {"id": "CQMF149A2210"}, "secondaryIdInfos": [{"id": "EudraCT number 2009-011539-10"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety of QMF149 Twisthaler\u00ae in Adolescent and Adult Patients With Asthma", "officialTitle": "A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler\u00ae (500/400 \u00b5g) and Mometasone Furoate Twisthaler\u00ae (400 \u00b5g) in Adolescent and Adult Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2012-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-07"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-14", "studyFirstSubmitQcDate": "2009-07-17", "studyFirstPostDateStruct": {"date": "2009-07-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-05-03", "resultsFirstSubmitQcDate": "2012-05-03", "resultsFirstPostDateStruct": {"date": "2012-06-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-08-21", "lastUpdatePostDateStruct": {"date": "2012-08-31", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler\u00ae 500/400 \u03bcg, a fixed dose combination of indacaterol 500 \u03bcg, a once daily \u03b22 agonist, and mometasone furoate 400 \u03bcg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial was to assess the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This was an event driven trial."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "LABA", "Safety"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 2283, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QMF149 Twisthaler\u00ae 500/400", "type": "EXPERIMENTAL", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)", "interventionNames": ["Drug: QMF149 Twisthaler\u00ae"]}, {"label": "Mometasone Twisthaler\u00ae", "type": "ACTIVE_COMPARATOR", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD", "interventionNames": ["Drug: Mometasone Twisthaler\u00ae"]}], "interventions": [{"type": "DRUG", "name": "QMF149 Twisthaler\u00ae", "description": "Once daily via multi-dose dry-powder inhaler", "armGroupLabels": ["QMF149 Twisthaler\u00ae 500/400"]}, {"type": "DRUG", "name": "Mometasone Twisthaler\u00ae", "description": "Once daily via multi-dose dry-powder inhaler", "armGroupLabels": ["Mometasone Twisthaler\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Serious Asthma Exacerbation", "description": "Defined as the number of days from start of treatment up to the first date when an asthma exacerbation becomes serious. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.", "timeFrame": "Up to 21 months"}], "secondaryOutcomes": [{"measure": "Cumulative Incidence of the First Serious Asthma Exacerbation Resulting in Hospitalization, Intubation or Death.", "description": "The number of patients with at least one serious asthma exacerbation over the course of the study. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.", "timeFrame": "up to 21 months"}, {"measure": "Patients With Asthma Exacerbations That Required Treatment With Systemic Corticosteroids", "description": "Number of patients requiring treatment with systemic corticosteroids (oral or parenteral) over the course of the study (up to 21 months).", "timeFrame": "Up to 21 months"}, {"measure": "Number of Patients With at Least One Asthma Worsening Post-baseline", "description": "The criterion for asthma worsening were: decrease in peak expiratory flow (PEF) \\>= 20% from mean baseline on \\>= 3 consecutive days, nighttime symptom score \\>= 2 on \\>= 2 consecutive nights, decrease in forced expiration volume in 1 second (FEV1) \\>=20% from baseline at evening visits, daytime symptom score of 3 or 4 on \\>= 2 consecutive days, requiring an urgent unscheduled visit for medical care, 24 hour rescue medication use \\>= 8 puffs on \\>= 2 consecutive days, and any other clinically important symptoms (pre-specified MedDRA preferred terms).", "timeFrame": "Up to 21 months"}, {"measure": "Change From Baseline in Trough Forced Expiration Volume in 1 Second (FEV1) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Trough FEV1 was measured 15 minutes before dosing; measurements within 6 hours of rescue medication use were set to missing. Repeated measures of analysis of covariance model: change from baseline to trough FEV1 = treatment + visit + treatment\\*visit interaction + baseline FEV1 + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}, {"measure": "Change From Baseline in Forced Expiration Volume in 1 Second (FEV1) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Change from baseline at final visit. FEV1 data taken within 6 hours of rescue medication was excluded from the analysis. Repeated measures of analysis of covariance model: change from baseline to final visit FEV1 = treatment + visit + treatment\\*visit interaction + baseline FEV1 + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months). At the following timepoints: 5 minutes post-dose, 30 minutes post-dose, 1 hour post-dose and 2 hours post-dose"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Change from baseline at final visit. FVC data taken within 6 hours of rescue medication was excluded from the analysis. Repeated measures of analysis of covariance model: change from baseline to final visit FVC = treatment + visit + treatment\\*visit interaction + baseline FVC + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months). At the following timepoints: 5 minutes post-dose, 30 minutes post-dose, 1 hour post-dose and 2 hours post-dose"}, {"measure": "Changes From Baseline in Morning Peak Expiratory Flow (PEF) and Trough Evening PEF Averaged Over the Entire Post-baseline Period", "description": "PEF was performed every morning and evening prior to study medication use except evenings on the day of clinic visits.\n\nBaseline is average over the last 14 days prior to start of treatment. Analysis of covariance model: change from baseline in PEF = treatment + baseline PEF + region + history of asthma related hospitalization in the past 12 months + history of asthma worsening in the past 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}, {"measure": "Change From Baseline in Percentage of Days With no Asthma Symptoms During the Morning, Daytime and Nighttime", "description": "Baseline = the last 14 days prior to start of treatment. Analysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}, {"measure": "Change From Baseline in Average Asthma Symptom Score Total, Daytime and Nighttime", "description": "Total asthma symptom score = morning symptoms (0, 1) + daytime score (0-4) + nighttime score (0-4). The range is from 0 to 9. A lower number indicates improvement. Baseline = the last 14 days prior to start of treatment.\n\nAnalysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}, {"measure": "Change From Baseline in Percentage of Days With no Rescue Medication Use During 24 Hours, Daytime and Nighttime", "description": "24 hours consists of both 12 hour daytime and 12 hour nighttime. Baseline = the last 14 days prior to start of treatment. Analysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) at Final Visit", "description": "The Asthma Control Questionnaire score ranges from 0 (good control of asthma) to 6 (poor control of asthma). A negative change in score indicates improvement in asthma control.\n\nRepeated measures of analysis of covariance model: change from baseline in ACQ score = treatment + visit + treatment\\*visit interaction + baseline ACQ score + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a documented diagnosis of persistent asthma and who were currently treated with or qualified for treatment with both ICS and long-acting beta2-agonist (LABA) combination\n* Patients demonstrating an increase in forced expiration volume in 1 second (FEV1) of \u2265 12% or \u2265 200 mLs within 30 minutes after administration of short-acting beta2-agonist (SABA)\n* Patients with an FEV1 \u2265 50% of predicted normal\n\nExclusion Criteria:\n\n* Patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD)\n* Patients who had an asthma attack/exacerbation requiring hospitalization/emergency room visit or respiratory tract infection within 1 month prior to randomization\n* Patients who had ever required ventilator support for respiratory failure\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Patients with concomitant pulmonary disease\n* Patients with certain cardiovascular co-morbid conditions\n* Patients with any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "70 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novartis Investigator Site", "city": "Buena Park", "state": "California", "zip": "90620", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "Novartis Investigator Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Novartis Investigator Site", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Novartis Investigator Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Novartis Investigator Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigator Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novartis Investigator Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigator Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigator Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Novartis Investigator Site", "city": "San Mateo", "state": "California", "zip": "94401", "country": "United States", "geoPoint": {"lat": 37.56299, "lon": -122.32553}}, {"facility": "Novartis Investigator Site", "city": "Vista", "state": "California", "zip": "92083", "country": "United States", "geoPoint": {"lat": 33.20004, "lon": -117.24254}}, {"facility": "Novartis Investigator Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Novartis Investigator Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigator Site", "city": "Engelwood", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "Novartis Investigator Site", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Novartis Investigator Site", "city": "Wheat Ridge", "state": "Colorado", "zip": "80033", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Novartis Investigator Site", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Novartis Investigator Site", "city": "Clearwater", "state": "Florida", "zip": "33765", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33157", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigator Site", "city": "Port Charlotte", "state": "Florida", "zip": "33952", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Novartis Investigator Site", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Novartis Investigative Site", "city": "South Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Novartis Investigator Site", "city": "Tampa", "state": "Florida", "zip": "33603", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novartis Investigative Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Novartis Investigative Site", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Novartis Investigative Site", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Novartis Investigator Site", "city": "Couer D'Alene", "state": "Idaho", "zip": "83814", "country": "United States", "geoPoint": {"lat": 47.67768, "lon": -116.78047}}, {"facility": "Novartis Investigator Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigator Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Novartis Investigator Site", "city": "River Forest", "state": "Illinois", "zip": "60305", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "Novartis Investigator Site", "city": "Skokie", "state": "Illinois", "zip": "60076", "country": "United States", "geoPoint": {"lat": 42.03336, "lon": -87.73339}}, {"facility": "Novartis Investigator Site", "city": "Springfield", "state": "Illinois", "zip": "62703", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Novartis Investigator Site", "city": "Evansville", "state": "Indiana", "zip": "47713", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Novartis Investigator Site", "city": "Indianapolis", "state": "Indiana", "zip": "46208", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Novartis Investigator Site", "city": "Iowa City", "state": "Iowa", "zip": "52240", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Novartis Investigator Site", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Novartis Investigator Site", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Novartis Investigator Site", "city": "Metarie", "state": "Louisiana", "zip": "70002", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Novartis Investigative Site", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21237", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigative Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Novartis Investigator Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigator Site", "city": "Plymouth", "state": "Minnesota", "zip": "55441", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"facility": "Novartis Investigator Site", "city": "Ozark", "state": "Missouri", "zip": "65721", "country": "United States", "geoPoint": {"lat": 37.02089, "lon": -93.20602}}, {"facility": "Novartis Investigator Site", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "Novartis Investigator Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigator Site", "city": "Warrensburg", "state": "Missouri", "zip": "64093", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "Novartis Investigator Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Novartis Investigator Site", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigator Site", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigative Site", "city": "Brick", "state": "New Jersey", "zip": "08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Novartis Investigative Site", "city": "Cedar Knolls", "state": "New Jersey", "zip": "07927", "country": "United States", "geoPoint": {"lat": 40.82204, "lon": -74.44876}}, {"facility": "Novartis Investigative Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Novartis Investigator Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87108", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Novartis Investigative Site", "city": "Mineola", "state": "New York", "zip": "11501", "country": "United States", "geoPoint": {"lat": 40.74927, "lon": -73.64068}}, {"facility": "Novartis Investigative Site", "city": "Newburgh", "state": "New York", "zip": "12550", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "Novartis Investigative Site", "city": "Rochester", "state": "New York", "zip": "14618-2638", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Novartis Investigative Site", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Novartis Investigative site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Novartis Investigator Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Novartis Investigator Site", "city": "Columbus", "state": "Ohio", "zip": "43213", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Novartis Investigator Site", "city": "Marion", "state": "Ohio", "zip": "43302", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"facility": "Novartis Investigator Site", "city": "Sylvania", "state": "Ohio", "zip": "43560", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73104", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigator Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigator Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigator Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Novartis Investigative Site", "city": "Blue Bell", "state": "Pennsylvania", "zip": "19422", "country": "United States", "geoPoint": {"lat": 40.15233, "lon": -75.26629}}, {"facility": "Novartis Investigative Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19115", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novartis Investigative site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novartis Investigative Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15221", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Novartis Investigator Site", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Novartis Investigative Site", "city": "Mt. Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Novartis Investigator Site", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Novartis Investigator Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigator Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigator Site", "city": "Dickinson", "state": "Texas", "zip": "77539", "country": "United States", "geoPoint": {"lat": 29.46079, "lon": -95.05132}}, {"facility": "Novartis Investigator Site", "city": "El Paso", "state": "Texas", "zip": "79925", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Novartis Investigator Site", "city": "Fort Worth", "state": "Texas", "zip": "76132", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Novartis Investigator Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novartis Investigative Site", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Novartis Investigative Site", "city": "Abingdon", "state": "Virginia", "zip": "24210", "country": "United States", "geoPoint": {"lat": 36.70983, "lon": -81.97735}}, {"facility": "Novartis Investigator Site", "city": "Kirkland", "state": "Washington", "zip": "98034", "country": "United States", "geoPoint": {"lat": 47.68149, "lon": -122.20874}}, {"facility": "Novartis Investigator Site", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Novartis Investigator Site", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Novartis Investigator Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53209", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Novartis Investigative Site", "city": "Belo Horizonte", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Novartis Investigative Site", "city": "Florianopolis", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Novartis Investigative Site", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Novartis Investigative Site", "city": "Rio de Janeiro", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Novartis Investigative Site", "city": "Salvador", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "Novartis Investigative Site", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigator Site", "city": "Boskovice", "country": "Czech Republic", "geoPoint": {"lat": 49.48751, "lon": 16.65997}}, {"facility": "Novartis Investigator Site", "city": "Breclav", "country": "Czech Republic", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "Novartis Investigator Site", "city": "Brno - Bohunice", "country": "Czech Republic"}, {"facility": "Novartis Investigator Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Novartis Investigator Site", "city": "Hradec Kralove", "country": "Czech Republic", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "Novartis Investigator Site", "city": "Jablonec nad Nisou", "country": "Czech Republic", "geoPoint": {"lat": 50.72431, "lon": 15.17108}}, {"facility": "Novartis Investigator Site", "city": "Kladno", "country": "Czech Republic", "geoPoint": {"lat": 50.14734, "lon": 14.10285}}, {"facility": "Novartis Investigator Site", "city": "Kutna Hora", "country": "Czech Republic", "geoPoint": {"lat": 49.94839, "lon": 15.26816}}, {"facility": "Novartis Investigator Site", "city": "Liberec", "country": "Czech Republic", "geoPoint": {"lat": 50.76711, "lon": 15.05619}}, {"facility": "Novartis Investigator Site", "city": "Most", "country": "Czech Republic", "geoPoint": {"lat": 50.50301, "lon": 13.63617}}, {"facility": "Novartis Investigator Site", "city": "Plzen", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Novartis Investigator Site", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Novartis Investigator Site", "city": "Tabor", "country": "Czech Republic", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Novartis Investigator Site", "city": "Teplice", "country": "Czech Republic", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Novartis Investigative Site", "city": "Trutnov", "country": "Czech Republic", "geoPoint": {"lat": 50.56101, "lon": 15.9127}}, {"facility": "Novartis Investigative Site", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Novartis Investigative Site", "city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Novartis Investigator Site", "city": "Deszk", "country": "Hungary", "geoPoint": {"lat": 46.21802, "lon": 20.24322}}, {"facility": "Novartis Investigative Site", "city": "Gyor", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "Novartis Investigative Site", "city": "Mosonmagyarovar", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Novartis Investigative Site", "city": "Nyiregyhaza", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Novartis Investigative Site", "city": "Tatabanya", "country": "Hungary", "geoPoint": {"lat": 47.58494, "lon": 18.39325}}, {"facility": "Novartis Investigative Site", "city": "Torokbalint", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Novartis Investigator Site", "city": "Chennai", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Novartis Investigator Site", "city": "Coimbatore", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Novartis Investigator Site", "city": "Hyderabaad", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigator Site", "city": "Indore", "country": "India", "geoPoint": {"lat": 22.71792, "lon": 75.8333}}, {"facility": "Novartis Investigator Site", "city": "Mangalore", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Novartis Investigator Site", "city": "Mumbai", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novartis Investigator Site", "city": "Nagpur", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigator Site", "city": "Panjim", "country": "India", "geoPoint": {"lat": 15.49574, "lon": 73.82624}}, {"facility": "Novartis Investigative Site", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Novartis Investigative SIte", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigator Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigator Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Novartis Investigator Site", "city": "Bardejov", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "Novartis Investigative Site", "city": "Bojnice", "country": "Slovakia", "geoPoint": {"lat": 48.78511, "lon": 18.5864}}, {"facility": "Novartis Investigator Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigator Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigator Site", "city": "Levice", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}, {"facility": "Novartis Investigator Site", "city": "Liptovsky Hradok", "country": "Slovakia", "geoPoint": {"lat": 49.03962, "lon": 19.72335}}, {"facility": "Novartis Investigator Site", "city": "Michalovce", "country": "Slovakia", "geoPoint": {"lat": 48.75434, "lon": 21.9195}}, {"facility": "Novartis Investigative Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigative Site", "city": "Surany", "country": "Slovakia", "geoPoint": {"lat": 48.08613, "lon": 18.18447}}, {"facility": "Novartis Investigator Site", "city": "Trencin", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Novartis Investigator Site", "city": "Vrable", "country": "Slovakia", "geoPoint": {"lat": 48.24371, "lon": 18.30846}}]}, "referencesModule": {"references": [{"pmid": "25649209", "type": "DERIVED", "citation": "Beasley RW, Donohue JF, Mehta R, Nelson HS, Clay M, Moton A, Kim HJ, Hederer BM. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. BMJ Open. 2015 Feb 3;5(2):e006131. doi: 10.1136/bmjopen-2014-006131."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "2283 patients were screened. 1518 patients were randomized.", "groups": [{"id": "FG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "FG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "755"}, {"groupId": "FG001", "numSubjects": "763"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "749"}, {"groupId": "FG001", "numSubjects": "759"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "561"}, {"groupId": "FG001", "numSubjects": "578"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "194"}, {"groupId": "FG001", "numSubjects": "185"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "74"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "Patient's inability to use device", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Abnormal test procedure results", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Abnormal laboratory values", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "BG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "749"}, {"groupId": "BG001", "value": "759"}, {"groupId": "BG002", "value": "1508"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.4", "spread": "14.75"}, {"groupId": "BG001", "value": "42.3", "spread": "14.58"}, {"groupId": "BG002", "value": "42.3", "spread": "14.66"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "436"}, {"groupId": "BG001", "value": "449"}, {"groupId": "BG002", "value": "885"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "313"}, {"groupId": "BG001", "value": "310"}, {"groupId": "BG002", "value": "623"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Serious Asthma Exacerbation", "description": "Defined as the number of days from start of treatment up to the first date when an asthma exacerbation becomes serious. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "months", "timeFrame": "Up to 21 months", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "749"}, {"groupId": "OG001", "value": "759"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.3", "lowerLimit": "0.0", "upperLimit": "19.6"}, {"groupId": "OG001", "value": "13.4", "lowerLimit": "0.0", "upperLimit": "20.3"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Incidence of the First Serious Asthma Exacerbation Resulting in Hospitalization, Intubation or Death.", "description": "The number of patients with at least one serious asthma exacerbation over the course of the study. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "up to 21 months", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "749"}, {"groupId": "OG001", "value": "759"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Patients With Asthma Exacerbations That Required Treatment With Systemic Corticosteroids", "description": "Number of patients requiring treatment with systemic corticosteroids (oral or parenteral) over the course of the study (up to 21 months).", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to 21 months", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "749"}, {"groupId": "OG001", "value": "759"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "171"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With at Least One Asthma Worsening Post-baseline", "description": "The criterion for asthma worsening were: decrease in peak expiratory flow (PEF) \\>= 20% from mean baseline on \\>= 3 consecutive days, nighttime symptom score \\>= 2 on \\>= 2 consecutive nights, decrease in forced expiration volume in 1 second (FEV1) \\>=20% from baseline at evening visits, daytime symptom score of 3 or 4 on \\>= 2 consecutive days, requiring an urgent unscheduled visit for medical care, 24 hour rescue medication use \\>= 8 puffs on \\>= 2 consecutive days, and any other clinically important symptoms (pre-specified MedDRA preferred terms).", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to 21 months", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "749"}, {"groupId": "OG001", "value": "759"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "533"}, {"groupId": "OG001", "value": "637"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Forced Expiration Volume in 1 Second (FEV1) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Trough FEV1 was measured 15 minutes before dosing; measurements within 6 hours of rescue medication use were set to missing. Repeated measures of analysis of covariance model: change from baseline to trough FEV1 = treatment + visit + treatment\\*visit interaction + baseline FEV1 + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "674"}, {"groupId": "OG001", "value": "699"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.025"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.024"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiration Volume in 1 Second (FEV1) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Change from baseline at final visit. FEV1 data taken within 6 hours of rescue medication was excluded from the analysis. Repeated measures of analysis of covariance model: change from baseline to final visit FEV1 = treatment + visit + treatment\\*visit interaction + baseline FEV1 + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months). At the following timepoints: 5 minutes post-dose, 30 minutes post-dose, 1 hour post-dose and 2 hours post-dose", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "578"}, {"groupId": "OG001", "value": "607"}]}], "classes": [{"title": "5 minutes post-dose (n = 578, 607)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.018"}, {"groupId": "OG001", "value": "-0.04", "spread": "0.018"}]}]}, {"title": "30 minutes post-dose (n = 576, 605)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.020"}, {"groupId": "OG001", "value": "-0.05", "spread": "0.020"}]}]}, {"title": "1 hour post-dose (n = 575, 602)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.021"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.021"}]}]}, {"title": "2 hours post-dose (n = 568, 601)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.022"}, {"groupId": "OG001", "value": "-0.05", "spread": "0.022"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) at Final Visit", "description": "Spirometry was conducted according to internationally accepted standards. Change from baseline at final visit. FVC data taken within 6 hours of rescue medication was excluded from the analysis. Repeated measures of analysis of covariance model: change from baseline to final visit FVC = treatment + visit + treatment\\*visit interaction + baseline FVC + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liter", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months). At the following timepoints: 5 minutes post-dose, 30 minutes post-dose, 1 hour post-dose and 2 hours post-dose", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "578"}, {"groupId": "OG001", "value": "607"}]}], "classes": [{"title": "5 minutes post-dose (n = 578, 607)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.023"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.023"}]}]}, {"title": "30 minutes post-dose (n = 576, 605)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.025"}, {"groupId": "OG001", "value": "-0.13", "spread": "0.024"}]}]}, {"title": "1 hour post-dose (n = 575, 602)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "spread": "0.025"}, {"groupId": "OG001", "value": "-0.13", "spread": "0.025"}]}]}, {"title": "2 hours post-dose (n = 568, 601)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.13", "spread": "0.026"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline in Morning Peak Expiratory Flow (PEF) and Trough Evening PEF Averaged Over the Entire Post-baseline Period", "description": "PEF was performed every morning and evening prior to study medication use except evenings on the day of clinic visits.\n\nBaseline is average over the last 14 days prior to start of treatment. Analysis of covariance model: change from baseline in PEF = treatment + baseline PEF + region + history of asthma related hospitalization in the past 12 months + history of asthma worsening in the past 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and at final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters per second", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "731"}, {"groupId": "OG001", "value": "748"}]}], "classes": [{"title": "Morning PEF (n = 730, 746)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.43", "spread": "0.075"}, {"groupId": "OG001", "value": "0.00", "spread": "0.075"}]}]}, {"title": "Evening PEF (n = 731, 748)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "spread": "0.076"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.075"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Days With no Asthma Symptoms During the Morning, Daytime and Nighttime", "description": "Baseline = the last 14 days prior to start of treatment. Analysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "731"}, {"groupId": "OG001", "value": "749"}]}], "classes": [{"title": "Morning (n = 730, 746)", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.3", "spread": "2.17"}, {"groupId": "OG001", "value": "18.4", "spread": "2.17"}]}]}, {"title": "Daytime (n = 731, 749)", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.1", "spread": "2.96"}, {"groupId": "OG001", "value": "19.5", "spread": "2.95"}]}]}, {"title": "Nighttime (n = 730, 746)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.6", "spread": "2.69"}, {"groupId": "OG001", "value": "17.3", "spread": "2.68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Average Asthma Symptom Score Total, Daytime and Nighttime", "description": "Total asthma symptom score = morning symptoms (0, 1) + daytime score (0-4) + nighttime score (0-4). The range is from 0 to 9. A lower number indicates improvement. Baseline = the last 14 days prior to start of treatment.\n\nAnalysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and endpoint were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "731"}, {"groupId": "OG001", "value": "749"}]}], "classes": [{"title": "Total (n = 708, 733)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "0.088"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.088"}]}]}, {"title": "Daytime (n = 731, 749)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.043"}, {"groupId": "OG001", "value": "-0.39", "spread": "0.043"}]}]}, {"title": "Nighttime (n = 730, 746)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.037"}, {"groupId": "OG001", "value": "-0.36", "spread": "0.037"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Days With no Rescue Medication Use During 24 Hours, Daytime and Nighttime", "description": "24 hours consists of both 12 hour daytime and 12 hour nighttime. Baseline = the last 14 days prior to start of treatment. Analysis of covariance model: Change from baseline = treatment + baseline value + region + history of asthma related hospitalization in past 12 months + history of asthma worsening in past 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "692"}, {"groupId": "OG001", "value": "711"}]}], "classes": [{"title": "24 hours (n = 669, 696)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.1", "spread": "2.88"}, {"groupId": "OG001", "value": "17.9", "spread": "2.88"}]}]}, {"title": "Daytime (n = 692, 711)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.6", "spread": "2.74"}, {"groupId": "OG001", "value": "13.8", "spread": "2.74"}]}]}, {"title": "Nighttime (n = 691, 708)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.6", "spread": "2.69"}, {"groupId": "OG001", "value": "14.5", "spread": "2.68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) at Final Visit", "description": "The Asthma Control Questionnaire score ranges from 0 (good control of asthma) to 6 (poor control of asthma). A negative change in score indicates improvement in asthma control.\n\nRepeated measures of analysis of covariance model: change from baseline in ACQ score = treatment + visit + treatment\\*visit interaction + baseline ACQ score + region + asthma related hospitalization in the last 12 months + asthma worsening in the last 12 months + African American patient.", "populationDescription": "Full analysis set: all randomized patients who received at least one dose of study medication. Participants with observations at both baseline and final visit were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to the end of treatment (varying durations, up to 21 months)", "groups": [{"id": "OG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)"}, {"id": "OG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "675"}, {"groupId": "OG001", "value": "687"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "0.052"}, {"groupId": "OG001", "value": "-0.32", "spread": "0.052"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "QMF149 Twisthaler\u00ae 500/400", "description": "QMF149 Twisthaler\u00ae (indacaterol maleate 500 \u00b5g/mometasone furoate 400 \u00b5g), once daily (QD)", "seriousNumAffected": 30, "seriousNumAtRisk": 749, "otherNumAffected": 510, "otherNumAtRisk": 749}, {"id": "EG001", "title": "Mometasone Twisthaler\u00ae", "description": "Mometasone Twisthaler\u00ae, 400 \u00b5g QD", "seriousNumAffected": 44, "seriousNumAtRisk": 759, "otherNumAffected": 477, "otherNumAtRisk": 759}], "seriousEvents": [{"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Stress cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Eye haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Abdominal hernia obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "Cyst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Multi-organ failure", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Abscess intestinal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "External ear cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Malaria", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Pneumococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 759}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Electrocardiogram T wave inversion", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Intervertebral disc disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Meningioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Osteochondroma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Carotid artery occlusion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Radicular pain", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Ectopic pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Abnormal behaviour", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Colpocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Ovarian mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 759}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 759}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 759}]}, {"term": "Sinus polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Inguinal hernia repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 759}]}], "otherEvents": [{"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 759}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 759}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 759}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 58, "numAtRisk": 759}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 759}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 759}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 759}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 112, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 106, "numAtRisk": 759}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 759}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 759}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 759}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 55, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 52, "numAtRisk": 759}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 83, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 96, "numAtRisk": 759}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 759}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 759}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 759}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 759}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 759}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 759}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 195, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 269, "numAtRisk": 759}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 266, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 63, "numAtRisk": 759}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 759}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 759}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 759}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 749}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 759}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "At 3", "relevance": "HIGH"}, {"id": "M245808", "name": "Maleic acid", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}